What is HC Wainwright’s Estimate for Rezolute Q1 Earnings?

Rezolute, Inc. (NASDAQ:RZLT) – HC Wainwright issued their Q1 2026 EPS estimates for shares of Rezolute in a research note issued to investors on Thursday, February 13th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.33) for the quarter. HC Wainwright currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11.

RZLT has been the topic of several other research reports. Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. Wedbush restated an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a research report on Monday, November 4th. JMP Securities raised their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a research report on Thursday. Finally, Guggenheim restated a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $24.38.

Rezolute Trading Down 4.2 %

NASDAQ RZLT opened at $4.61 on Monday. The firm has a market capitalization of $267.10 million, a price-to-earnings ratio of -3.63 and a beta of 1.10. The firm’s 50 day simple moving average is $4.86 and its 200 day simple moving average is $4.90. Rezolute has a 1 year low of $1.13 and a 1 year high of $6.19.

Insider Transactions at Rezolute

In other Rezolute news, CFO Daron Evans purchased 9,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $4.60 per share, for a total transaction of $41,400.00. Following the completion of the acquisition, the chief financial officer now owns 140,900 shares in the company, valued at approximately $648,140. This trade represents a 6.82 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 18.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Rezolute

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new position in shares of Rezolute during the third quarter worth $42,000. Alpine Global Management LLC acquired a new position in shares of Rezolute during the fourth quarter worth $54,000. MML Investors Services LLC acquired a new position in shares of Rezolute during the third quarter worth $57,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Rezolute in the third quarter valued at $65,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after buying an additional 9,000 shares during the period. Institutional investors and hedge funds own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.